MRKR NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Marker Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 1.13 USD
-7.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -23.6% below the Trend Line and sits at 19.4% of its 52-week range. The latest completed week returned -7.4%, after a -23.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 21 out of 100
Latest Close 1.13 USD 31 Jul 2026
1W Return -7.4% latest completed week
4W Return -23.1% short-term follow-through
12W Return -22.6% quarterly tape
Trend Breadth 36.5% 19 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -7.4% Latest completed week; four-week move -23.1%. Indicator stack 20/24 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 53/100 42 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -23.6% below the Trend Line and sits at 19.4% of its 52-week range. The latest completed week returned -7.4%, after a -23.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2212-week average 0.37

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.22Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -23.1% over four weeks, -22.6% over 12 weeks, and -16.3% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-7.4%
4W-23.1%
12W-22.6%
26W-29.4%
52W-16.3%
Active trend streak0 weeks
Active weeks in one year19
Trend breadth36.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.07Latest activity-pressure read.
Pressure change-86.2%Four-week change in activity pressure.
Leadership-21.82Latest relative-leadership reading.
RS change-316.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 76% Model confidence 73%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength52/100Blend of value, momentum, and quality. Underlying universe rank 49; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality49/100Profitability and accounting quality. Underlying universe rank 52; rank 1 is best.
Momentum50/100Medium-term price momentum. Underlying universe rank 51; rank 1 is best.
Growth51/100Revenue and earnings growth. Underlying universe rank 50; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
6.4x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-145.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-374.4%
Operating profit retained from revenue.
Free-cash-flow margin
-247.6%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-43.9%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-48.5%
Net share repurchases relative to market value.
Shareholder yield
-48.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 42 relevant articles.

11 positive · 24 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-54.1%Distance below the 52-week high.
13-week volatility7.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2615 weeks finished lower.
Best week+32.6%Week of 10 Apr.
Worst week-15.7%Week of 24 Apr.
Latest week-7.4%Week of 31 Jul.

Shape of recent returns

Strong gains4
Modest gains6
Flat weeks1
Modest losses7
Sharp losses8
Recent vol7.1%13-week weekly-return volatility.
Base vol11.1%52-week weekly-return volatility.
Up/down split26/24Count of positive and negative weeks in the 52-week window.
Average skew8.3% / -8.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape24/100

Trend, activity pressure, participation, and risk combine to a 24/100 tape read.

 Indicator analysis17/100

Latest 12-week confirmation: trend 2/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.22; No reversal markers Factors49/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 96 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment53/100

Weighted news tone is neutral across 42 relevant articles.

Marker Therapeutics Inc (MRKR) Institutional Confidence Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20261.13 USD-7.4%1.48 USD2.66 USD-1.07-21.82212.1KOff
24 Jul 20261.22 USD-6.9%1.49 USD2.68 USD-0.79-15.75199.3KOff
17 Jul 20261.31 USD-13.2%1.50 USD2.72 USD-0.62-11.76175.8KOff
10 Jul 20261.51 USD2.7%1.50 USD2.75 USD-0.45-3.53618.8KOff
3 Jul 20261.47 USD11.8%1.50 USD2.78 USD-0.57-5.24251.0KOff
26 Jun 20261.31 USD-1.1%1.49 USD2.79 USD-0.57-15.12229.2KOff
19 Jun 20261.33 USD-3.6%1.49 USD2.80 USD-0.31-18.59203.7KOff
12 Jun 20261.38 USD-2.8%1.48 USD2.82 USD-0.21-14.00328.7KOff
5 Jun 20261.42 USD-9.6%1.47 USD2.83 USD-0.30-10.34316.1KOff
29 May 20261.57 USD12.1%1.45 USD2.84 USD-0.35-6.41304.2KOn
22 May 20261.40 USD-1.4%1.43 USD2.84 USD-0.59-14.77297.6KOff
15 May 20261.42 USD-2.7%1.42 USD2.84 USD-0.70-12.72248.4KOn
8 May 20261.46 USD0.0%1.40 USD2.84 USD-0.63-10.65432.9KOn
1 May 20261.46 USD4.3%1.39 USD2.84 USD-0.51-6.00297.1KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.